Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Dec;47(12):3525-3542.
doi: 10.1007/s11064-022-03697-8. Epub 2022 Aug 17.

Cell Death Mechanisms in Cerebral Ischemia-Reperfusion Injury

Qian Zhang  1   2   3   4 , Meng Jia  2   3   4 , YunFu Wang  5 , Qun Wang  2   4 , Jianping Wu  6   7   8   9
Affiliations
Review

Cell Death Mechanisms in Cerebral Ischemia-Reperfusion Injury

Qian Zhang et al. Neurochem Res. 2022 Dec.

Abstract

Ischemic stroke is one of the major causes of morbidity and mortality, affecting millions of people worldwide. Inevitably, the interruption of cerebral blood supply after ischemia may promote a cascade of pathophysiological processes. Moreover, the subsequent restoration of blood flow and reoxygenation may further aggravate brain tissue injury. Although recombinant tissue plasminogen activator (rt-PA) is the only approved therapy for restoring blood perfusion, the reperfusion injury and the narrow therapeutic time window restrict its application for most stroke patients. Increasing evidence indicates that multiple cell death mechanisms are relevant to cerebral ischemia-reperfusion injury, including apoptosis, necrosis, necroptosis, autophagy, pyroptosis, ferroptosis, and so on. Therefore, it is crucial to comprehend various cell death mechanisms and their interactions. In this review, we summarize the various signaling pathways underlying cerebral ischemia-reperfusion injury and elaborate on the crosstalk between the different mechanisms.

Keywords: Apoptosis; Autophagy; Cerebral ischemia–reperfusion; Necroptosis; Necrosis.

PubMed Disclaimer

References

    1. GBD (2016) Stroke Collaborators (2019) Global, regional, and national burden of stroke, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 18:439–458. https://doi.org/10.1016/S1474-4422(19)30034-1 - DOI
    1. Powers WJ (2020) Acute ischemic stroke. N Engl J Med 383:252–260. https://doi.org/10.1056/NEJMcp1917030 - DOI - PubMed
    1. Del Zoppo GJ, Saver JL, Jauch EC, Adams HP, Council AHAS (2009) Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/ American Stroke Association. Stroke 40:2945–2948. https://doi.org/10.1161/STROKEAHA.109.192535 - DOI - PubMed - PMC
    1. IST-3 Collaborative Group, Sandercock P, Wardlaw JM, Lindley RI, Dennis M, Cohen G, Murray G, Innes K, Venables G, Czlonkowska A, Kobayashi A, Ricci S, Murray V, Berge E, Slot KB, Hankey GJ, Correia M, Peeters A, Matz K, Lyrer P, Gubitz G, Phillips SJ, Arauz A (2012) The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): A randomised controlled trial. Lancet 379:2352–2363. https://doi.org/10.1016/S0140-6736(12)60768-5 - DOI
    1. Kalogeris T, Baines CP, Krenz M, Korthuis RJ (2012) Cell biology of ischemia/reperfusion injury. Int Rev Cell Mol Biol 298:229–317. https://doi.org/10.1016/B978-0-12-394309-5.00006-7 - DOI - PubMed - PMC

Substances

LinkOut - more resources